This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • ROP anti-VEGF treatment review

ROP anti-VEGF treatment review
Reviewed by Fiona Rowe

3 June 2021 | Fiona Rowe (Prof) | EYE - Paediatrics, EYE - Strabismus
Share This

The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP, vascularisation of peripheral retina after treatment and reduced incidence of high myopia. Ocular side-effects include abnormalities in peripheral retina and posterior pole, development of retinal detachment, greater potential for later recurrence than with retinal photocoagulation, asymmetric responses / outcomes and potential for anterior segment complications. Systemic side-effects include the confirmed presence of anti-VEGF drugs in systemic circulation after intravitreal injections. Further review sections include comparison of Bevacizumab and Ranibizumab, effect of decreased dosage on anti-VEGF therapy, anti-VEGF and laser combination therapy, and current clinical trials for ROP. The authors conclude that there remains a need for a large multicentre randomised control trial (RCT) with long-term follow-up of patients receiving anti-VEGF treatment for type I ROP and addressing the efficacy and safety of various anti-VEGF drugs.

Update on the use of anti-VEGF drugs in the treatment of retinopathy of prematurity.
Seery CW, Betesh S, Guo S, et al.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2020;57:351-62.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency